Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Ball

Showing results (391-400 of 449) with videos related to

Pageof 45
Sort By:
The New England Journal of Medicine|June 18, 2025
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney CancerRamaprasad Srinivasan, Sandeep Gurram, Eric A Singer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancerRazelle Kurzrock, Steven I Sherman, Douglas W Ball, et al.
MMWR. Morbidity and Mortality Weekly Report|September 19, 2014
Influenza vaccination coverage among health care personnel--United States, 2013-14 influenza seasonCarla L Black, Xin Yue, Sarah W Ball, et al.
Journal of Medical Genetics|September 24, 2024
A novel pathogenic germline chromosome 3 inversion in von Hippel-Lindau diseaseCathy D Vocke, Christopher J Ricketts, Svetlana Pack, et al.
Urologic Oncology|August 23, 2025
Renal surgery following HIF-2α antagonist therapy: Surgical indications, outcomes and growth kineticsDaniel Nethala, Braden Millan, Jason Hyman, et al.
Cancer|April 28, 2015
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentMaria E Cabanillas, Martin Schlumberger, Barbara Jarzab, et al.
Urology|June 18, 2023
PRDM10 RCC: A Birt-Hogg-Dubé-like Syndrome Associated With Lipoma and Highly Penetrant, Aggressive Renal Tumors Morphologically Resembling Type 2 Papillary Renal Cell CarcinomaLaura S Schmidt, Cathy D Vocke, Christopher J Ricketts, et al.
Brain Research|July 1, 2008
Neurochemical characterization of tyrosine hydroxylase-immunoreactive interneurons in the developing rat cerebral cortexStephen E Asmus, Emily K Anderson, Mark W Ball, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 27, 2009
NCCN task force: clinical utility of PET in a variety of tumor typesDonald A Podoloff, Douglas W Ball, Edgar Ben-Josef, et al.
Journal of the American College of Cardiology|February 16, 2010
A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trialMartin B Leon, Laura Mauri, Jeffrey J Popma, et al.
Pageof 45

Showing results (391-400 of 449) with videos related to

Sort By:
Pageof 45
The New England Journal of Medicine|June 18, 2025
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney CancerRamaprasad Srinivasan, Sandeep Gurram, Eric A Singer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancerRazelle Kurzrock, Steven I Sherman, Douglas W Ball, et al.
MMWR. Morbidity and Mortality Weekly Report|September 19, 2014
Influenza vaccination coverage among health care personnel--United States, 2013-14 influenza seasonCarla L Black, Xin Yue, Sarah W Ball, et al.
Journal of Medical Genetics|September 24, 2024
A novel pathogenic germline chromosome 3 inversion in von Hippel-Lindau diseaseCathy D Vocke, Christopher J Ricketts, Svetlana Pack, et al.
Urologic Oncology|August 23, 2025
Renal surgery following HIF-2α antagonist therapy: Surgical indications, outcomes and growth kineticsDaniel Nethala, Braden Millan, Jason Hyman, et al.
Cancer|April 28, 2015
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentMaria E Cabanillas, Martin Schlumberger, Barbara Jarzab, et al.
Urology|June 18, 2023
PRDM10 RCC: A Birt-Hogg-Dubé-like Syndrome Associated With Lipoma and Highly Penetrant, Aggressive Renal Tumors Morphologically Resembling Type 2 Papillary Renal Cell CarcinomaLaura S Schmidt, Cathy D Vocke, Christopher J Ricketts, et al.
Brain Research|July 1, 2008
Neurochemical characterization of tyrosine hydroxylase-immunoreactive interneurons in the developing rat cerebral cortexStephen E Asmus, Emily K Anderson, Mark W Ball, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 27, 2009
NCCN task force: clinical utility of PET in a variety of tumor typesDonald A Podoloff, Douglas W Ball, Edgar Ben-Josef, et al.
Journal of the American College of Cardiology|February 16, 2010
A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trialMartin B Leon, Laura Mauri, Jeffrey J Popma, et al.
Pageof 45